[Event Report] The First Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC) (January 22, 2020)
date : 2/11/2020
Tags: AMR
Nikkei Inc. and AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) jointly held the First Sub-committee on AMR of the Nikkei Asia Africa Conference on Communicable Diseases – Asia Africa Medical Innovation Consortium (AMIC).
At this first sub-committee, participants from academia, the Government, industry and civil society discussed potential policy options to ensure sustainable research and development (R&D) for antimicrobials.
Participants agreed to continue to discuss the state of the antimicrobial market in working groups toward the eventual formulation of a concrete proposal on ways to incentivize antimicrobial R&D in the future.
■Overview
Date and time: Wednesday, January 22, 2020
Organizer: AMR Alliance Japan (Secretariat: HGPI)
■Program
The role of the AMR sub-committee
Mitsuru Miyata (Adviser, Medical and Healthcare Division, Nikkei Business Publications, Inc.)
Shigeru Omi (President, Japan Community Health care Organization (JCHO) / Regional Director Emeritus, Regional Office for the Western Pacific (WPRO), World Health Organization (WHO))
AMR Alliance Japan
Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute (AMR Alliance Japan Secretariat))
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Discussion —Policy options to revitalize the antimicrobial industry
From the perspective of the Cabinet Secretariat:
Hiroyuki Noda (Councilor, Coordination Office of Measures on Emerging Infectious Diseases, Office of Pandemic Influenza and New Infectious Diseases Preparedness and Response, Cabinet Secretariat)
From the perspective of the Ministry of Health, Labour and Welfare:
Manami Yanagawa (Chief, Tuberculosis and Infectious Diseases Control Division, Ministry of Health, Labour and Welfare (MHLW))
From the perspective of the pharmaceutical industry
Takeo Morooka (Executive Officer, Head of Health Policy and Corporate Support, MSD K.K.) Takuko Sawada (Executive Vice President, Shionogi & Co., Ltd.)
Chairs:
Shigeru Omi (President, Japan Community Health care Organization (JCHO) / Regional Director Emeritus, Regional Office for the Western Pacific (WPRO), World Health Organization (WHO))
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Facilitator:
Ryoji Noritake (CEO, Board Member, Health and Global Policy Institute (AMR Alliance Japan Secretariat))
Top Research & Recommendations Posts
- [Public Comment Submission] “The 7th Science, Technology and Innovation Basic Plan” (Draft) (February 19, 2026)
- [Research Report] Energy Conservation and Greenhouse Gas Emissions Reduction in Healthcare Facilities: Case Studies from New Construction and Facility Renewal (March 16, 2026)
- [Research Report] Perceptions, Knowledge, Actions and Perspectives of Healthcare Organizations in Japan in Relation to Climate Change and Health: A Cross-Sectional Study (November 13, 2025)
- [Research Report] The 2025 Public Opinion Survey on Healthcare in Japan (March 17, 2025)
- [Policy Recommendations] Policy Recommendations in the Field of Blood Disorders “Building a Healthcare Ecosystem Centered on Patients and Those Affected” (April 13, 2026)
- [Event Report and Discussion Points] AI Diagnostic Support Project Expert Meeting: “The Roles of Industry, Government, Academia, and Civil Society in the Era of AI-Assisted Diagnosis” (May 25, 2026)
- [Research Report] The 2026 Public Opinion Survey on Healthcare in Japan (February 13, 2026)
- [Policy Recommendations] Mental Health Project: Recommendations on Three Issues in the Area of Mental Health (July 4, 2025)
- [Policy Recommendations] Dementia Project “The Future of Dementia Policy Surrounding Families and Others Who Care for People with Dementia” (April 27, 2026)
- [Policy Recommendations] Reshaping Japan’s Immunization Policy for Life Course Coverage and Vaccine Equity: Challenges and Prospects for an Era of Prevention and Health Promotion (April 25, 2025)
Featured Posts
-
2026-05-13
[Registration Open] HGPI Salon 2025-2026 Looking Ahead to the Future of Japan’s Social Security System “Session 5: The Value of Healthcare in Society – Perspectives from the Reiwa Era” (June 29, 2026)
-
2026-05-15
[Registration Open] (Webinar) The 2nd J-PEP Seminar – A New Framework for Providing Information on Clinical Trial Participant Recruitment – Legal Points to Consider from the Perspective of Meaningful Involvement (June 15, 2026)
-
2026-05-18
[Registration Open] Kick-off Panel Discussion “From Japan and Africa, in Discussion with the World: Cultivating Together a Philosophical Dialogue on Health” (June 15, 2026)
-
2026-05-19
[Registration Open] (Webinar) HGPI Special Seminar “Building a Society Where People Live with Blood Disorders: The Future of Blood Disorder Policy as Examined from the Frontlines of Home-Based Care × Lived Experience Research” (June 12, 2026)
-
2026-06-04
[Registration Open] (Webinar) The 3rd J-PEP Seminar “Social Participation of People with Intractable Diseases and the Potential of a New Way of Working — ‘RD Workers’ — Lessons from Policy Advocacy Practice” (July 22, 2026)



